Terumo 2022 Blood Cell Technologies Growth Strategy Investor Presentation

Terumo Corporation presents its growth strategy for the Blood and Cell Technologies business as part of its GS26 mid-to-long-term strategy. The presentation outlines balanced growth across three business segments with expansion in therapeutic areas including stroke, aortic, peripheral, and cancer treatments alongside diabetes management and cardiac/vascular procedures.